Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Oncolytics Biotech Inc.NASDAQ: ONCY

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -CA$22.31K, compared with -CA$19K a year earlier. Trailing-twelve-month gross profit was -CA$119.31K.

Context

  • Gross profit grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -CA$22.31K or moves back toward the trailing-twelve-month quarterly average of -CA$29.83K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$22.31K— QoQ
Last fiscal yearDec 2025
-CA$70K+19.5% YoY
LTMMar 2026
-CA$119.31K+26.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.4%——
1 year+19.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
(70K) CAD
Year-over-year change
+19.5%

Gross Profit vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.6% is the 4th highest of 8, against a peer median of +16.2%.
ONCY Competitors
Gross Profit for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.92M USD+177.2%—99.8%
SRZNSurrozen, Inc.LTM Mar 2026$7.43M USD-34.0%-31.7%99.1%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K USD+100.0%——
TILInstil Bio, Inc.LTM Mar 2026-$24K USD+96.8%——
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$119.31K CAD+26.6%——
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K USD———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K USD-100.6%——
CLNNClene Inc.LTM Mar 2026-$244K USD-188.4%-29.4%182.1%
Peer median (excluding ONCY) —+16.2%-29.4%99.5%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue360.58K301.11K298.59K87K70K
Gross Profit(360.58K)(301.11K)(298.59K)(87K)(70K)
Gross Margin—————
Research & Development10.31M11.85M13.12M21.65M18.27M
Selling, General & Admin10.26M8.53M11.62M13.34M21.15M
Operating Expenses20.56M20.38M24.74M34.98M39.41M
Depreciation & Amortization360.58K301.11K298.59K102K96.05K
EBITDA(20.58M)(18.71M)(20.19M)(34.88M)(39.41M)
EBITDA Margin—————
Operating Income(20.93M)(20.68M)(25.04M)(34.98M)(39.41M)
Operating Margin—————
Interest Income99K528K1.33M1.2M529.64K
Interest Expense00000
Other Income / Expenses(15.88K)1.67M4.55M3.4M61.75K
Income Before Tax(20.94M)(19.01M)(20.49M)(31.58M)(39.35M)
Pre-Tax Margin—————
Income Tax Expense39.42K64.52K71.87K130K108.4K
Net Income(20.98M)(19.08M)(20.56M)(31.71M)(39.46M)
Net Margin—————
EPS (Basic)(0.49)(0.44)(0.41)(0.41)(0.41)
EPS (Diluted)(0.49)(0.44)(0.41)(0.41)(0.41)
Weighted Avg Shares53.51M58.03M67.62M76.48M95.86M
Weighted Avg Shares (Diluted)53.51M58.03M67.62M76.48M95.86M

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.